Superiority of polatuzumab vedotin over other novel agents in previously untreated ABC-type diffuse large B-cell lymphoma: a network meta-analysis of 20 RCTs

Because of lacking of head-to-head comparison among polatuzumab (Pola) vedotin and other novel agents for untreated diffuse large B-cell lymphoma (DLBCL), the optimal option remains undefined. We searched twelve relevant published reports, covering 8376 subjects. Interestingly, the PFS benefit with...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of hematology 2023-05, Vol.102 (5), p.1011-1017
Hauptverfasser:	Sheng, Zhixin, Li, Dianfang, Chen, Bing, Zhao, Chunwu, Zhang, Wenxing, Ding, Baolong, Wang, Lida
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Cyclophosphamide - adverse effects Doxorubicin - adverse effects Hematology Humans Immunotherapy Inhibitor drugs Lymphoma Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - pathology Medicine Medicine & Public Health Meta-analysis Monoclonal antibodies Network Meta-Analysis Oncology Prednisone - adverse effects Randomized Controlled Trials as Topic Review Article Rituximab - therapeutic use Targeted cancer therapy Thoracic surgery Vincristine - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Because of lacking of head-to-head comparison among polatuzumab (Pola) vedotin and other novel agents for untreated diffuse large B-cell lymphoma (DLBCL), the optimal option remains undefined. We searched twelve relevant published reports, covering 8376 subjects. Interestingly, the PFS benefit with Pola-R-CHP over other regimens was found prominently in those B-cell-like type (ABC-type) patients. For those ABC-type patients, the PFS advantage with Pola-R-CHP was statistically significant, when compared to R-CHOP+Bort (HR: 0.52, P =0.02), R-CHOP+Ibru (HR: 0.43, P =0.001), R-CHOP+Lena (HR: 0.51, P =0.009), G-CHOP (HR: 0.46, P =0.008), and R-CHOP (HR: 0.40, P
ISSN:	0939-5555 1432-0584
DOI:	10.1007/s00277-023-05161-1